Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in childhood cancer
This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It affects up to 10 per cent of women of reproductive age around the world
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
